May 07, 2024 / 08:00AM GMT
Klas Palin - Erik Penser Bank - Analyst
Hello and welcome to this live Q&A with Senzime's, CEO, Philip Siberg. Thank you. We will start off with a short introduction of the company and the quarterly reports go ahead.
Philip Siberg - Senzime AB(publ)-Chief Executive Officer
All right. Thank you. Okay. Senzime medical device company, where the field of perioperative precision based patient monitoring, I would hit into the numbers right away and come back into the company. Okay, but Q1 was another record sales growth quarter. We saw good growth, 66% growth. We reached SEK12.1 million in sales. And the US is the main driver of 75% of the business and also the main driver of growth.
The, what we can see here is that [today]. I'm sorry, the dynamics of the business up the run rate really took off. So I'm losing my voice again. Okay. But let me just take it second.
Yes. So that's not a motivated.
Okay. So momentum in the business is good. And if you look at our net sales rolling 12 months, we're in a
Q1 2024 Senzime AB (publ) Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot